JO
TNGX icon

John Overdeck’s Tango Therapeutics TNGX Stock Holding History

John Overdeck’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.56M Buy
241,783
+68,651
+40% +$1.7M 0.01% 1752
2026
Q1 		$3.62M Buy
173,132
+28,700
+20% +$399K ﹤0.01% 2261
2025
Q4 		$1.28M Hold
144,432
– – ﹤0.01% 2757
2025
Q3 		$1.21M Buy
144,432
+122,214
+550% +$827K ﹤0.01% 2451
2025
Q2 		$114K Sell
22,218
-30,684
-58% -$75.9K ﹤0.01% 2986
2025
Q1 		$72.5K Buy
52,902
+7,906
+18% +$19.4K ﹤0.01% 3001
2024
Q4 		$139K Sell
44,996
-23,166
-34% -$108K ﹤0.01% 2928
2024
Q3 		$525K Sell
68,162
-22,616
-25% -$216K ﹤0.01% 2456
2024
Q2 		$779K Sell
90,778
-216,457
-70% -$1.67M ﹤0.01% 2124
2024
Q1 		$2.44M Buy
307,235
+70,843
+30% +$759K 0.01% 1345
2023
Q4 		$2.34M Buy
236,392
+104,301
+79% +$905K 0.01% 1411
2023
Q3 		$1.49M Buy
132,091
+70,531
+115% +$430K ﹤0.01% 1665
2023
Q2 		$204K Sell
61,560
-11,696
-16% -$42.1K ﹤0.01% 2639
2023
Q1 		$289K Buy
+73,256
New +$425K ﹤0.01% 2433

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

John Overdeck's TNGX Position: Q2 2026 in Review

John Overdeck increased its Tango Therapeutics (TNGX) stake by 40% in Q2 2026, buying an estimated $1.7M and bringing the position to 241,783 shares worth $7.56M. The position accounts for 0.01% of the portfolio, ranked #1752.

John Overdeck first reported a position in TNGX in Q1 2023 and has held it in 14 quarters since. 246 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • John Overdeck held 241,783 shares of Tango Therapeutics worth $7.56M as of Q2 2026.
  • John Overdeck bought 68,651 Tango Therapeutics shares in Q2 2026, an estimated $1.7M.
  • Tango Therapeutics made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1752 holding.
  • John Overdeck first reported a position in Tango Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • 246 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.